To The Moon

What a monster quarter from $Xeris Pharmaceuticals Inc(XERS)$ Stock is pushing brand-new 52-week highs ($11.36+ pre-market) and it's completely deserved. Look at the numbers they just reported: $107.2M in revenue (beat by $5.5M) and positive GAAP EPS of $0.06 (crushed the -$0.01 estimate). Recorlev is taking massive market share in Cushing's, gross margins are holding above 86%, and management just gave a long-term 2030 revenue target exceeding $1 Billion. Add in the fact that they retired $34M in convertible debt earlier and their Phase 3 for XP-8121 starts around year-end, and this isn't just a speculative biotech anymore—it's a profitable commercial compounder. My execution plan: Current: ~$10.41 – $10.75 (Surging to $11.36+) Buy the retest: $1

While a lot of stocks are trying to dig their way out of October holes, $Flywire Corp.(FLYW)$ just blew the roof off its 52-week high ($20.24) on Wednesday, ripping +12.1% to $21.48 and trading right at the high of the day. Look at how clean Tuesday night’s Q3 report was: Crushed the top line: Revenue jumped 25.1% YoY to $250.3M (beating estimates by $17.3 million!), with Total Payment Volume up 27.7% to $17.8 billion across education, healthcare, and travel. Massive operating leverage: Adjusted EBITDA surged 39.2% YoY to $79.5M, pushing EBITDA margins to 32.5% (+310 bps YoY). They even released their $39M US tax valuation allowance because domestic profitability is now locked in. Raised full-year guidance: Hiked full-year FX-neutral revenue growt